MedTrace Logo

The Potential of Candesartan to Retard the Progression of Aortic Stenosis

NCT00699452 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2009-05-19

No results posted yet for this study

Summary

The present study defines a blinded, randomized, placebo-controlled, prospective study, the aim of which is to determine the influence of effective treatment with Type 1 angiotensin II (Ang II) receptor (AT-1R) antagonist, using candesartan (target dose 16 mg) on stenotic aortic valves. The investigators will specifically quantify whether candesartan attenuates the key pathogenic mechanisms of aortic valve stenosis, namely inflammation, fibrosis, elastin degradation, calcification, and neovascularization.

Conditions

  • Aortic Valve Stenosis

Interventions

DRUG

candesartan

Candesartan 8 mg/d for two weeks, then 16 mg/d until valve replacement surgery (approximately 3 months)

DRUG

placebo

placebo

Sponsors & Collaborators

  • AstraZeneca

    collaborator INDUSTRY

  • University of Helsinki

    lead OTHER

Principal Investigators

  • Markku Kupari, MD, PhD · Division of Cardiology, Helsinki University Central Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-05-31
Primary Completion
2012-12-31
Completion
2014-12-31

Countries

  • Finland

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00699452 on ClinicalTrials.gov